Quantum Genomics to meet investors at the European Large & Midcap Event, October 7 & 8, 2015

Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, will be participating at the 15^th edition of the European Large & Midcap Event, a conference dedicated to meetings between European listed companies and institutional investors, to be held in Paris on October 7 & 8, 2015.

On that occasion, Lionel Ségard, Chairman and CEO of Quantum Genomics, and Marc Karako, Chief Financial Officer, will comment on the Company's latest progress, in particular the Phase IIa clinical trials currently under way for high blood pressure of its drug candidate QGC001 and in preparation stage for the treatment of heart failure.

QGC001 is the first of a new class of therapeutics for the treatment of complicated/resistant hypertension, called Brain Aminopeptidase A Inhibitors (BAPAIs). The objective of QGC001 is to offer an alternative therapy for the treatment of high blood pressure, aimed particularly at patients with a Low Renin High Vasopressin (LRHV) hormonal profile.